Thaindian News

London, April 7 (IANS) Men who ejaculated within 36 seconds of penetration lasted six times longer after using a topical spray five minutes before sex, according to the latest study.
Three hundred men with clinically diagnosed lifelong premature ejaculation (PE) from 31 centres in Britain, Czech Republic, Hungary and Poland, were randomly divided into two groups.

Two hundred used the PSD502 spray, which contains 7.5 mg of lidocaine and 2.5 mg of prilocaine, and 100 used a placebo spray with no active ingredients.

Every time they had intercourse during the three-month study period, each couple measured the time from vaginal penetration to ejaculation with a stopwatch. The men were asked to abstain from sexual activity or masturbation for 24 hours before each recorded encounter.

The time from penetration to ejaculation increased from an average of 0.6 minutes to 3.8 minutes in the medicated group and to just 1.1 minutes in the placebo group.

When these figures were adjusted to take account of any variations between the two groups, these showed that the treatment group were able to last 6.3 times longer after penetration when they used the spray. The placebo group lasted 1.7 times longer.

“Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy,” says lead researcher W. Wallace Dinsmore, professor at the Royal Victoria Hospital, Britain.

The research team used the evidence-based definition of lifelong PE developed by the International Society for Sexual Medicine to select their study subjects. This states that ejaculation occurs within one minute of vaginal penetration in the majority of encounters.

“Because this definition was only launched in 2008, studies have yet to determine the prevalence of lifelong PE in the male population,” said Dinsmore. “But previous research suggests that as many as 40 percent of men will experience premature ejaculation at some time in their lives.”

The 300 men who took part in the phase three, multi-centre, double-blind, random study had an average age of 35. The majority had used other treatments before, the most common being oral anti-depressants, said a Royal Victoria release.

These findings were published in the April issue of British Journal of Urology International.